Sasha Siegel

Sasha Siegel began their work experience in 2017 as a Postdoctoral Research Fellow at the Wellcome Trust Sanger Institute. They held this role until November 2020. In 2020, they transitioned to the role of MalariaGEN Amplicon Surveillance Lead at the Wellcome Sanger Institute, where they stayed until April 2022. In April 2022, Sasha Siegel became the Genomic Surveillance Lead for MalariaGEN at the Wellcome Sanger Institute, where they led the scientific strategy for infectious disease genomics, epidemiology, and translational research. They built and implemented advanced genomic surveillance products and services for malaria-endemic regions. They held this position until April 2023. In 2022, Sasha Siegel also worked as a Director at Healthwave Digital Innovations. Currently, they are the Vice President of Disease Outcomes at Airfinity Ltd, beginning in April 2023.

Sasha Siegel completed a Bachelor of Arts and Science (BAS) degree in Biology and Music from Rollins College, where they studied from 2006 to 2010. Following this, they pursued a Doctor of Philosophy (PhD) degree in Molecular Medicine, specializing in Allergy, Immunology & Infectious Diseases at the University of South Florida from 2010 to 2016.